Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome.

19th September 2021

Jagdis A, Vadas P. Omalizumab effectively prevents recurrent refractory anaphylaxis in a patient with monoclonal mast cell activation syndrome. Ann Allergy Asthma Immunol. 2014;113(1):115-116. doi:10.1016/j.anai.2014.05.001

View

Become a friend

Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives. Please click on Data Protection at the bottom of the page to see our Data Protection Information.

Become a friend

Donate

Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference for sufferers of MCAS.

Make a donation

Close